哈利库 (尼提西诺):第一个FDA批准的疾病修饰疗法,用于治疗alkaptonuria
Harshika Khaim Chandani1, Syeda Fadak Zahra Hujjat2, Devya Khaim Chandani3
1Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.
Annals of medicine and surgery (2012)
|December 11, 2025
概括
阿尔卡普顿尿症 (AKU),一种罕见的代谢障碍,现在有了第一个疾病修饰疗法,尼提西 (Harliku). 这种治疗显著降低了同源性酸 (HGA) 水平,提供了一种超出支持性护理的新方法.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔卡普顿尿症 (AKU) 是一种罕见的自体递归代谢障碍,由同质化1,2-二氧化原酶缺乏症引起.
- 这种缺乏导致同质性酸 (HGA) 积累,导致,骨关节病和全身并发症.
- 目前对AKU的治疗主要是支持性,重点是骨科手术和缓解症状.
研究的目的:
- 评估尼提西诺作为阿尔卡普顿尿病的第一个疾病修饰疗法的疗效和安全性.
- 评估尼松对代谢控制,功能结果和AKU患者潜在的心脏保护作用的影响.
主要方法:
- 尼提西是4-基酸二氧化原酶的竞争性抑制剂.
- 像SONIA 2这样的研究,由NIH资助,监测了接受尼提西诺的患者.
- 评估了生物化学标志物,包括尿液HGA分泌,以及临床结果.
主要成果:
- 尼提西能在尿液中减少HGA分泌的95%以上.
- 长期的代谢控制被证明与尼提西治疗.
- 观察到改善的功能结果和潜在的心脏保护作用.
结论:
- 尼提西 (Harliku) 是第一个FDA批准的疗法,可以修改AKU的进展,将治疗从症状转变为疾病修改.
- 虽然有希望,但像铁血症这样的潜在风险需要谨慎的饮食管理和持续的患者监测.
- 这一进步代表了AKU管理的重要一步,并为罕见代谢障碍的未来治疗提供了一个模型.
相关概念视频
Phase II Reactions: Acetylation Reactions
732
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
732
2° Amines to N-Nitrosamines: Reaction with NaNO2
5.3K
Secondary amines react with nitrous acid to form N-nitrosamines, as depicted in Figure 1. Nitrous acid, a weak and unstable acid, is formed in situ from an aqueous solution of sodium nitrite and strong acids, such as hydrochloric acid or sulfuric acid, in cold conditions. In the presence of an acid, the nitrous acid gets protonated. The subsequent loss of water results in the formation of the electrophile known as nitrosonium ion.
5.3K
NF-κB-dependent Signaling Pathway
9.7K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
415
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
415
Nephrotic Syndrome I : Introduction
469
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
469
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
436
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
436


